Molecular Diagnostics

In Other News

• Blood-Based MRD Monitoring Supports Relapse Prevention in Leukemia

• Genomic Test Predicts Chemotherapy Benefit in Metastatic Prostate Cancer

• Blood Protein Markers Flag Multiple Sclerosis Risk Years Before Diagnosis

• MCED Blood Test Reduces Stage IV Cancer Diagnoses in NHS Trial

• Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests

• Digital PCR Assays Support Surveillance of Bundibugyo Ebolavirus Outbreak

• ClearNote Health to Present Pancreatic Cancer Blood Test Data at ASCO 2026

• Blood-Based Proteomic Test May Predict Treatment Response in Non-Small Cell Lung Cancer

• Ultrasensitive MRD Blood Test Detects Early Breast Cancer Recurrence

• Position Statements Outline Evidence Standards for Multi-Cancer Detection Tests

• Gene Fusion Patterns May Flag High Risk Solitary Fibrous Tumors

• Tumor Genome Marker May Predict Treatment Benefit in Pediatric Cancers

• New RNA Origami Method Supports Faster Targeted Testing for Repeat Expansion Disorders

• FDA Approves Expanded Liquid Biopsy Panel for Advanced Cancer Profiling

• Microbial Saliva Test Could Help Triage Esophageal Cancer Risk

• Expanded DPYD Genotyping Test Supports Safer Chemotherapy Dosing

• Multi-Omics Profiling Helps Predict BCG Response and Recurrence in Bladder Cancer

• New Computational Tool Reveals Genetic Driver of Idiopathic Neuropathy

• Breast Cancer-Specific Signatures Link Genome Instability to Outcomes

• Whole-Genome MRD Test Detects Early Recurrence in Muscle-Invasive Bladder Cancer

• Blood Test Detects Early Nonresponse in Metastatic Prostate Cancer

• FDA-Cleared Genomic Profiling Assay Guides Treatment Selection in Solid Tumors

• ctDNA Blood Test Could Help Guide Radiotherapy in Patients with Limited Metastases